{"id":396848,"date":"2025-04-03T08:11:16","date_gmt":"2025-04-03T06:11:16","guid":{"rendered":"https:\/\/medizinonline.com\/durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc\/"},"modified":"2025-04-03T08:12:39","modified_gmt":"2025-04-03T06:12:39","slug":"durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/pt-pt\/durvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc\/","title":{"rendered":"Durvalumab aprovado como primeira imunoterapia para doentes com LS-SCLC"},"content":{"rendered":"\n<p><strong>O durvalumab foi aprovado como monoterapia na Su\u00ed\u00e7a para o tratamento de doentes adultos com cancro do pulm\u00e3o de pequenas c\u00e9lulas irressec\u00e1vel (LS-SCLC, <em>cancro do pulm\u00e3o de pequenas c\u00e9lulas em fase limitada) <\/em>cuja doen\u00e7a n\u00e3o tenha progredido ap\u00f3s quimiorradioterapia (CRT) \u00e0 base de platina [1]. Oferece uma nova op\u00e7\u00e3o de tratamento que demonstrou melhorar a sobreviv\u00eancia dos doentes com esta forma agressiva de cancro do pulm\u00e3o. <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fdurvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>O durvalumab foi aprovado como monoterapia na Su\u00ed\u00e7a para o tratamento de doentes adultos com cancro do pulm\u00e3o de pequenas c\u00e9lulas irressec\u00e1vel (LS-SCLC, cancro do pulm\u00e3o de pequenas c\u00e9lulas em&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/pt-pt\/a-minha-conta\/pacotes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/pt-pt\/iniciar-sessao\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fpt-pt%2Fdurvalumab-aprovado-como-primeira-imunoterapia-para-doentes-com-ls-sclc%2F\">Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":396850,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinoma pulmonar de pequenas c\u00e9lulas","footnotes":""},"category":[11521,11542,11379,11547,11551],"tags":[11726,23070,23766,13523,81887,37888,20520],"powerkit_post_featured":[],"class_list":["post-396848","post","type-post","status-publish","format-standard","has-post-thumbnail","category-estudos","category-mercado-medicina","category-oncologia-pt-pt","category-pneumologia-pt-pt","category-rx-pt","tag-cancro-do-pulmao","tag-cancro-do-pulmao-de-pequenas-celulas","tag-durvalumab-pt-pt","tag-imunoterapia","tag-lc-sclc-pt-pt","tag-quimioradioterapia","tag-sclc-pt-pt","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-03 08:24:12","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"pt_PT","wpml_translations":{"es_ES":{"locale":"es_ES","id":396842,"slug":"durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc","post_title":"Durvalumab aprobado como primera inmunoterapia para pacientes con LS-SCLC","href":"https:\/\/medizinonline.com\/es\/durvalumab-aprobado-como-primera-inmunoterapia-para-pacientes-con-ls-sclc\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/396848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=396848"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/396848\/revisions"}],"predecessor-version":[{"id":398120,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/posts\/396848\/revisions\/398120"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media\/396850"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=396848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/category?post=396848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=396848"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/pt-pt\/wp-json\/wp\/v2\/powerkit_post_featured?post=396848"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}